NO20042100L - Fremgangsmate for administrering av et tymosinalfa 1-peptid - Google Patents

Fremgangsmate for administrering av et tymosinalfa 1-peptid

Info

Publication number: NO20042100L
Authority: NO; Norway
Prior art keywords: peptide; alpha; thymosinal; administering; patient
Prior art date: 2001-11-01

Application number

NO20042100A

Other languages

English (en)

Other versions

NO327101B1 (no

NO20042100D0 (no

Inventor

Alfred R Rudolph

Cynthia W Tuthill

Original Assignee

Sciclone Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-01

Filing date

2004-05-21

Publication date

2004-05-21

2004-05-21 Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc

2004-05-21 Publication of NO20042100D0 publication Critical patent/NO20042100D0/no

2004-05-21 Publication of NO20042100L publication Critical patent/NO20042100L/no

2009-04-20 Publication of NO327101B1 publication Critical patent/NO327101B1/no

Links

238000000034 method Methods 0.000 title abstract 2
108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
108010078233 Thymalfasin Proteins 0.000 abstract 3
102400000800 Thymosin alpha-1 Human genes 0.000 abstract 2
NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 abstract 2
229960004231 thymalfasin Drugs 0.000 abstract 2
238000001802 infusion Methods 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1
230000000638 stimulation Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Biotechnology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

NO20042100A 2001-11-01 2004-05-21 Anvendelse av tymosinalfa 1 peptid NO327101B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33087401P	2001-11-01	2001-11-01
PCT/US2002/035093 WO2003037366A1 (en)	2001-11-01	2002-11-01	Method of administering a thymosin alpha 1 peptide

Publications (3)

Publication Number	Publication Date
NO20042100D0 NO20042100D0 (no)	2004-05-21
NO20042100L true NO20042100L (no)	2004-05-21
NO327101B1 NO327101B1 (no)	2009-04-20

Family

ID=23291672

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20042100A NO327101B1 (no)	2001-11-01	2004-05-21	Anvendelse av tymosinalfa 1 peptid

Country Status (19)

Country	Link
US (2)	US20050049191A1 (no)
EP (1)	EP1450850B1 (no)
JP (1)	JP2005511563A (no)
KR (1)	KR20050042229A (no)
CN (1)	CN1582163A (no)
AT (1)	ATE481980T1 (no)
AU (1)	AU2002363248B2 (no)
BR (1)	BR0213823A (no)
CA (1)	CA2464307A1 (no)
DE (1)	DE60237784D1 (no)
EA (1)	EA008536B1 (no)
ES (1)	ES2353379T3 (no)
IL (2)	IL161665A0 (no)
MX (1)	MXPA04004187A (no)
NO (1)	NO327101B1 (no)
NZ (1)	NZ532763A (no)
PL (1)	PL208388B1 (no)
UA (1)	UA80957C2 (no)
WO (1)	WO2003037366A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004048971A1 (en) *	2002-11-25	2004-06-10	Sciclone Pharmaceuticals, Inc.	Methods of protecting against radiation damage using alpha thymosin
EP1613340B1 (en)	2003-03-28	2010-05-12	SciClone Pharmaceuticals, Inc.	Treatment of aspergillus infections with thymosin alpha 1
US8017129B2 (en) *	2006-06-15	2011-09-13	SciClone Pharmaceuticals International Ltd	Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
US20080300166A1 (en) *	2007-06-01	2008-12-04	Sciclone Pharmaceuticals, Inc.	Treatment of Melanoma with Alpha Thymosin Peptides
CA2708168A1 (en) *	2007-12-14	2009-06-25	Sciclone Pharmaceuticals, Inc.	Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
CN102458470B (zh)	2009-05-08	2016-01-20	赛生制药有限公司	作为疫苗增强剂的α胸腺素肽
EP2838551A4 (en) *	2012-03-08	2016-02-24	Sciclone Pharmaceuticals Inc	USE OF THYMOSIN ALPHA FOR THE TREATMENT OF PURULENT RHINO-SINUSITIS
US20130296223A1 (en)	2012-03-30	2013-11-07	Sciclone Pharmaceuticals, Inc.	Use of thymosin alpha for the treatment of sepsis
RU2020142556A (ru) *	2014-10-21	2021-02-12	Сайклон Фармасьютикалз Интернешнл Лтд.	Способ лечения рака или его метастаза с помощью пептида тимозина-альфа и ингибитора белка запрограммированной гибели клеток-1 (pd-1)
WO2016129005A1 (en)	2015-02-09	2016-08-18	Luigina Romani	Thymosin alpha 1 for use in treatment of cystic fibrosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4447233A (en) *	1981-04-10	1984-05-08	Parker-Hannifin Corporation	Medication infusion pump
US4444757A (en) *	1981-11-16	1984-04-24	Research Corporation	Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
TW224053B (no) *	1991-09-13	1994-05-21	Paul B Chretien
TW249754B (no) *	1993-10-26	1995-06-21	Alpha I Biomedicals Inc
US5760000A (en) *	1994-05-13	1998-06-02	University Technologies International,Inc.	Inhibition of liver cancer by the use of GnRH and GnRH analogs
US5888980A (en) *	1994-06-30	1999-03-30	Bio-Logic Research And Development Corporation	Compositions for enhancing immune function
US5632983A (en) *	1994-11-17	1997-05-27	University Of South Florida	Method for treating secondary immunodeficiency
US5849596A (en) *	1996-07-08	1998-12-15	Food Industry Research And Development Institute	Process for determining the smoke content of edible oil
EP1301619B1 (en) *	2000-07-14	2006-10-18	Transform Pharmaceuticals, Inc.	System and method for optimizing tissue barrier transfer of compounds
CA2427430A1 (en) *	2000-11-02	2002-06-13	Research Foundation Of City University Of New York	Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4

2002
- 2002-01-11 UA UA20040504064A patent/UA80957C2/uk unknown
- 2002-11-01 ES ES02802520T patent/ES2353379T3/es not_active Expired - Lifetime
- 2002-11-01 AU AU2002363248A patent/AU2002363248B2/en not_active Ceased
- 2002-11-01 EA EA200400591A patent/EA008536B1/ru not_active IP Right Cessation
- 2002-11-01 PL PL370430A patent/PL208388B1/pl not_active IP Right Cessation
- 2002-11-01 JP JP2003539708A patent/JP2005511563A/ja active Pending
- 2002-11-01 AT AT02802520T patent/ATE481980T1/de not_active IP Right Cessation
- 2002-11-01 BR BR0213823-9A patent/BR0213823A/pt not_active IP Right Cessation
- 2002-11-01 KR KR1020047006674A patent/KR20050042229A/ko not_active Ceased
- 2002-11-01 EP EP02802520A patent/EP1450850B1/en not_active Expired - Lifetime
- 2002-11-01 IL IL16166502A patent/IL161665A0/xx active IP Right Grant
- 2002-11-01 CA CA002464307A patent/CA2464307A1/en not_active Abandoned
- 2002-11-01 WO PCT/US2002/035093 patent/WO2003037366A1/en not_active Ceased
- 2002-11-01 MX MXPA04004187A patent/MXPA04004187A/es active IP Right Grant
- 2002-11-01 CN CNA02821871XA patent/CN1582163A/zh active Pending
- 2002-11-01 DE DE60237784T patent/DE60237784D1/de not_active Expired - Lifetime
- 2002-11-01 NZ NZ532763A patent/NZ532763A/en not_active IP Right Cessation
- 2002-11-01 US US10/493,848 patent/US20050049191A1/en not_active Abandoned
2004
- 2004-04-29 IL IL161665A patent/IL161665A/en not_active IP Right Cessation
- 2004-05-21 NO NO20042100A patent/NO327101B1/no not_active IP Right Cessation
2010
- 2010-05-07 US US12/775,986 patent/US20100221274A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PL208388B1 (pl)	2011-04-29
MXPA04004187A (es)	2004-07-08
CN1582163A (zh)	2005-02-16
DE60237784D1 (de)	2010-11-04
EP1450850B1 (en)	2010-09-22
US20100221274A1 (en)	2010-09-02
ATE481980T1 (de)	2010-10-15
NZ532763A (en)	2008-01-31
EP1450850A4 (en)	2005-11-30
IL161665A (en)	2011-03-31
EP1450850A1 (en)	2004-09-01
AU2002363248B2 (en)	2007-11-22
EA008536B1 (ru)	2007-06-29
IL161665A0 (en)	2004-09-27
PL370430A1 (en)	2005-05-30
WO2003037366A1 (en)	2003-05-08
BR0213823A (pt)	2004-08-31
CA2464307A1 (en)	2003-05-08
NO327101B1 (no)	2009-04-20
UA80957C2 (en)	2007-11-26
NO20042100D0 (no)	2004-05-21
US20050049191A1 (en)	2005-03-03
ES2353379T3 (es)	2011-03-01
KR20050042229A (ko)	2005-05-06
EA200400591A1 (ru)	2004-10-28
JP2005511563A (ja)	2005-04-28

Legal Events

Date	Code	Title	Description
2013-06-24	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
DK0490991T3 (da)	1993-11-29	Doseringsform til oral administration af hypoglykæmisk glipizid
IL165531A0 (en)	2006-01-15	GLP-1 and methods for treating diabetes
KR930702022A (ko)	1993-09-08	인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
EA200000468A1 (ru)	2000-12-25	Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
NO306377B1 (no)	1999-11-01	Doseform for avgivelse av et medikament
CA2129541A1 (en)	1994-07-07	Method of Promoting Nitrogen Retention in Humans
DK0600079T3 (da)	2002-04-15	Oral 1alpha-hydroxyprævitamin D
WO2001060381B1 (en)	2001-11-01	Nucleoside analogs with carboxamidine-modified bicyclic base
DE60327843D1 (de)	2009-07-16	Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
EA200400548A1 (ru)	2005-06-30	Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
NO20042100L (no)	2004-05-21	Fremgangsmate for administrering av et tymosinalfa 1-peptid
DE69615984D1 (de)	2001-11-22	Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen
JP2002530353A5 (no)	2006-12-14
AR023185A1 (es)	2002-09-04	Tratamiento de cancer mejorado con temozolomida
NO20042055L (no)	2004-05-18	Tymosinalfa 1-peptid/polymerkonjugater
DE60031259D1 (de)	2006-11-23	Nährstoffe aus sojabohnenprotein
MY106603A (en)	1995-06-30	Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
TW200517119A (en)	2005-06-01	Method of treatment using interferon-tau
ATE205397T1 (de)	2001-09-15	Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen
DE60015306D1 (de)	2004-12-02	Verwendung von beta interferon zur herstellung eines arzneimittels zur behandlung von ewings sarkom und eoe
RU2004111044A (ru)	2005-10-10	Препарат для лечения геморрагического инсульта и способ лечения геморрагического инсульта
MD1780F1 (en)	2001-11-30	Method of treatment of patients with hepatic cirrhosis
JPS6447715A (en)	1989-02-22	Improver for ovulation inductive pregnant genital physiological dysfunction
MX9306998A (es)	1995-01-31	Una composicion terapeutica de tandospirona y forma de dosis paraadministrarla.
KR920007624A (ko)	1992-05-27	단백질 의약품의 경구투여용 조성물